Profound Medical (TSX-V:PRN) has received Frost & Sullivan’s 2016 European Prostate Ablation Systems New Product Innovation Award for its TULSA-PRO system.
TULSA-PRO, which received CE Mark approval in April 2016, combines real-time MRI with transurethral, robotically driven therapeutic ultrasound and closed-loop thermal feedback control designed to provide precise ablation of the prostate, while simultaneously protecting critical surrounding anatomy from potential side effects.
Profound announced the first European sales of TULSA-PRO systems in Spain, UK, and Germany earlier this year.
In a statement, Arun Menawat, Profound’s CEO, said the F&S award provides further validation that TULSA-PRO “represents an attractive clinical option for patients with localized prostate cancer and comes at an opportune time as we continue to build awareness and adoption of this important new therapy in Europe.”
Arjunvasan Ambigapathy, an industry analyst in Technical Insights for Frost & Sullivan, said that by demonstrating industry-leading best practice initiatives, the company succeeded in exclusively differentiating its offering as a safe and effective alternative to existing expensive treatment modalities for prostate cancer.
“The competitive advantage built by Profound Medical has improved its brand reputation as being the only company in the world developing and commercializing a transurethral ultrasound ablation technology,” he added.
